TL;DR: The cannabis sector closed the July 25 trading week with the AdvisorShares Pure US Cannabis ETF (MSOS) posting gains and institutional attention building ahead of what analysts are calling the sector’s most consequential two-week reporting window in 2026. Tilray Brands (TLRY) is positioned to deliver Q4 FY2026 results within three trading sessions, opening an earnings calendar that extends through Organigram Holdings on August 11. With the DEA’s administrative law process advancing through its evidence phase, the combination of approaching earnings clarity and regulatory progress sets a constructive tone heading into the final week of July.
Market Analysis — Week in Review
The week ending July 25 offered cannabis equity investors a familiar but increasingly important signal: sector stability alongside improving fundamental narratives. MSOS advanced Friday, building on intraday gains that reflected institutional flow into diversified cannabis exposure ahead of the August earnings cluster.
Among the multi-state operators, the week’s price action reinforced the bifurcation between operators demonstrating operational discipline and those still working through legacy scale challenges. Green Thumb Industries (GTBIF), the sector’s benchmark profitable MSO, continued to trade at approximately half its average analyst consensus price target — a persistent valuation gap that institutional commentary increasingly attributes to federal policy overhang rather than fundamental deterioration. Green Thumb reports Q2 2026 earnings on August 4.
Verano Holdings (VRNOF) held near $2.71 through the week, with the company’s established multistate dispensary footprint providing a floor as investors await Q2 data. Cresco Labs (CRLBF) maintained its positioning as a differentiated operator through its wholesale distribution infrastructure — an asset class that carries compounding strategic value as smaller operators exit the market and consolidation accelerates.
On the Canadian side, Organigram Holdings (OGI) continued to draw attention from international-focused cannabis investors following Thursday’s 3% gain. The company’s BAT Alliance partnership and expanding international product channels are generating increasing sell-side interest ahead of its August 11 earnings report. Canopy Growth (CGC), despite trading near multi-year price lows, retains a $365 million cash position that provides meaningful optionality as the Canadian LP market continues to evolve.
Regulatory and Market Context
The DEA’s rescheduling proceedings moved further into their formal evidence phase this week, with administrative law judge hearings continuing to build the federal record required before any final scheduling rule can be promulgated. Market participants are broadly modeling formal rulemaking completion in late 2026 to early 2027 — a timeline that has shifted investor calculus from binary event risk to measured positioning ahead of a structural change.
The financial implications of Schedule III reclassification remain substantial. Elimination of Section 280E’s application to cannabis businesses would allow operators to deduct ordinary and necessary business expenses for the first time, producing material improvements to net income and operating cash flow across the sector. For large MSOs like Green Thumb, Curaleaf, and Cresco — which have each built scale under the full weight of 280E — rescheduling represents a structural earnings inflection rather than a marginal line item improvement.
Any administrative disclosures from the ALJ evidence phase next week should be monitored closely by investors managing near-term positioning. The proceedings can surface new information on rescheduling timeline and the scope of the final rule.
Week Ahead — July 28 Trading Week
The most significant near-term catalyst is Tilray Brands’ Q4 FY2026 earnings report, arriving within three trading sessions. Tilray’s result will be evaluated on two primary dimensions: the performance of its international cannabis segment — now the company’s primary organic growth driver — and the trajectory of its U.S. beverage alcohol portfolio, which management has positioned as a strategic hedge ahead of federal cannabis reform.
Beyond Tilray, the first full week of August brings Green Thumb Industries on August 4, Canopy Growth around August 7, and Organigram on August 11. Each report will contribute to the most comprehensive fundamental update the sector has received since Q1 2026. Cannabis investors who have been working with limited earnings visibility will have a substantially clearer picture of operator health by mid-August.
Sector-wide, investors should also watch for any developments in the SAFE Banking Act’s legislative trajectory. The combination of a rescheduling process nearing its formal conclusion and ongoing Senate interest in cannabis banking access represents the most favorable federal policy backdrop the sector has faced since recreational legalization began expanding state by state.
Conclusion
The close of July 25 places cannabis equity investors at the inflection point before a high-information period. Tilray earnings arriving next week, followed by the densest MSO reporting cluster of 2026, will provide the fundamental anchoring the sector has needed to resolve the persistent valuation gap between analyst targets and current prices. Investors maintaining diversified exposure while monitoring individual operator earnings execution can track sector movements in real time via the cannabis stock tracker.
Sheeba M. covers cannabis market intelligence for Weedstock. This analysis is for informational purposes only and does not constitute investment advice.